Cover Image
Market Research Report

Global Myasthenia Gravis Drugs Industry Research Report, Growth Trends and Competitive Analysis 2018-2025

Published by QYResearch Product code 750046
Published Content info 127 Pages
Delivery time: 3-5 business days
Price
Back to Top
Global Myasthenia Gravis Drugs Industry Research Report, Growth Trends and Competitive Analysis 2018-2025
Published: November 29, 2018 Content info: 127 Pages
Description

Acetylcholine esterase (AChE) inhibitors are considered to be the basic treatment of myasthenia gravis (MG). Edrophonium is primarily used as a diagnostic tool owing to its short half-life. Pyridostigmine is used for long-term maintenance.

The market is witnessing the rapid development of novel drugs such as monoclonal antibodies, which is one of the primary factors driving this market's growth prospects. Most drug manufacturers are increasingly focussing on the development of monoclonal antibodies, as they act specifically on target cells; thereby, leading to lower side effects. Since conventional therapies such as acetylcholinesterase inhibitor, oral steroids, and immunomodulatory agents are associated with more side effects, physicians prefer to prescribe high efficacious monoclonal antibodies.

In 2018, the global Myasthenia Gravis Drugs market size was xx million US$ and is forecast to xx million US in 2025, growing at a CAGR of xx% from 2018. In this study, 2017 has been considered as the base year and 2018 to 2025 as the forecast period to estimate the market size for Myasthenia Gravis Drugs.

This study researches the market size of Myasthenia Gravis Drugs, presents the global Myasthenia Gravis Drugs sales and revenue by companies, regions, type and application, history breakdown data from 2013 to 2018, and forecast to 2025.

This report focuses on the key data information of Myasthenia Gravis Drugs in key regions like North America, Europe, Asia Pacific, Central & South America, and Middle East & Africa, presents sales, revenue, market share, growth rate of Myasthenia Gravis Drugs for each region and countries in each region.

For top companies, this report investigates and analyzes the sales, revenue, market share and growth rate for the top players, key data from 2013 to 2018.

This report also studies the global market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels, distributors and Porter's Five Forces Analysis.

This report includes the following manufacturers; we can also add the other companies as you want.

  • Flamel Technologies
  • Roche
  • Grifols
  • Pfizer
  • Shire
  • Novartis
  • Valeant
  • Alexion
  • Catalyst
  • CSL
  • Curavac
  • Cytokinetics
  • Galencia
  • GlaxoSmithKline
  • Lupin Pharmaceuticals
  • Mitsubishi Tanabe Pharma

Market Segment by Product Type

  • Anticholinesterases
  • Immunosuppressants
  • Intravenous Immune Globulins

Market Segment by Application

  • Hospitals
  • Clinics

Market size split by Region

  • North America
    • United States
    • Canada
    • Mexico
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Indonesia
    • Malaysia
    • Philippines
    • Thailand
    • Vietnam
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Russia
  • Central & South America
    • Brazil
    • Rest of Central & South America
  • Middle East & Africa
    • GCC Countries
    • Egypt
    • South Africa

The study objectives are:

  • To analyze and research the global Myasthenia Gravis Drugs status and future forecast, involving capacity, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
  • To present the key Myasthenia Gravis Drugs manufacturers, capacity, production, revenue, market share, and recent development for key players.
  • To split the breakdown data by regions, type, companies and applications.
  • To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
  • To identify significant trends, drivers, influence factors in global and regions.
  • To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Myasthenia Gravis Drugs are as follows:

  • History Year: 2013-2018
  • Base Year: 2017
  • Estimated Year: 2018
  • Forecast Year 2018 to 2025
Table of Contents

Table of Contents

1. Report Overview

  • 1.1. Research Scope
  • 1.2. Major Manufacturers Covered in This Report
  • 1.3. Market Segment by Type
    • 1.3.1. Global Myasthenia Gravis Drugs Market Size Growth Rate by Type
    • 1.3.2. Anticholinesterases
    • 1.3.3. Immunosuppressants
    • 1.3.4. Intravenous Immune Globulins
  • 1.4. Market Segment by Application
    • 1.4.1. Global Myasthenia Gravis Drugs Market Share by Application (2018-2025)
    • 1.4.2. Hospitals
    • 1.4.3. Clinics
  • 1.5. Study Objectives
  • 1.6. Years Considered

2. Global Growth Trends

  • 2.1. Global Myasthenia Gravis Drugs Market Size
    • 2.1.1. Global Myasthenia Gravis Drugs Revenue 2013-2025
    • 2.1.2. Global Myasthenia Gravis Drugs Sales 2013-2025
  • 2.2. Myasthenia Gravis Drugs Growth Rate by Regions
    • 2.2.1. Global Myasthenia Gravis Drugs Sales by Regions 2013-2018
    • 2.2.2. Global Myasthenia Gravis Drugs Revenue by Regions 2013-2018
  • 2.3. Industry Trends
    • 2.3.1. Market Top Trends
    • 2.3.2. Market Drivers

3. Market Share by Manufacturers

  • 3.1. Myasthenia Gravis Drugs Sales by Manufacturers
    • 3.1.1. Myasthenia Gravis Drugs Sales by Manufacturers 2013-2018
    • 3.1.2. Myasthenia Gravis Drugs Sales Market Share by Manufacturers 2013-2018
  • 3.2. Revenue by Manufacturers
    • 3.2.1. Myasthenia Gravis Drugs Revenue by Manufacturers (2013-2018)
    • 3.2.2. Myasthenia Gravis Drugs Revenue Share by Manufacturers (2013-2018)
    • 3.2.3. Global Myasthenia Gravis Drugs Market Concentration Ratio (CR5 and HHI)
  • 3.3. Myasthenia Gravis Drugs Price by Manufacturers
  • 3.4. Key Manufacturers Myasthenia Gravis Drugs Plants/Factories Distribution and Area Served
  • 3.5. Date of Key Manufacturers Enter into Myasthenia Gravis Drugs Market
  • 3.6. Key Manufacturers Myasthenia Gravis Drugs Product Offered
  • 3.7. Mergers & Acquisitions, Expansion Plans

4. Market Size by Type

  • 4.1. Sales and Revenue for Each Type
    • 4.1.1. Anticholinesterases Sales and Revenue (2013-2018)
    • 4.1.2. Immunosuppressants Sales and Revenue (2013-2018)
    • 4.1.3. Intravenous Immune Globulins Sales and Revenue (2013-2018)
  • 4.2. Global Myasthenia Gravis Drugs Sales Market Share by Type
  • 4.3. Global Myasthenia Gravis Drugs Revenue Market Share by Type
  • 4.4. Myasthenia Gravis Drugs Price by Type

5. Market Size by Application

  • 5.1. Overview
  • 5.2. Global Myasthenia Gravis Drugs Sales by Application

6. North America

  • 6.1. North America Myasthenia Gravis Drugs Breakdown Data by Company
  • 6.2. North America Myasthenia Gravis Drugs Breakdown Data by Type
  • 6.3. North America Myasthenia Gravis Drugs Breakdown Data by Application
  • 6.4. North America Myasthenia Gravis Drugs Breakdown Data by Countries
    • 6.4.1. North America Myasthenia Gravis Drugs Sales by Countries
    • 6.4.2. North America Myasthenia Gravis Drugs Revenue by Countries
    • 6.4.3. United States
    • 6.4.4. Canada
    • 6.4.5. Mexico

7. Europe

  • 7.1. Europe Myasthenia Gravis Drugs Breakdown Data by Company
  • 7.2. Europe Myasthenia Gravis Drugs Breakdown Data by Type
  • 7.3. Europe Myasthenia Gravis Drugs Breakdown Data by Application
  • 7.4. Europe Myasthenia Gravis Drugs Breakdown Data by Countries
    • 7.4.1. Europe Myasthenia Gravis Drugs Sales by Countries
    • 7.4.2. Europe Myasthenia Gravis Drugs Revenue by Countries
    • 7.4.3. Germany
    • 7.4.4. France
    • 7.4.5. UK
    • 7.4.6. Italy
    • 7.4.7. Russia

8. Asia Pacific

  • 8.1. Asia Pacific Myasthenia Gravis Drugs Breakdown Data by Company
  • 8.2. Asia Pacific Myasthenia Gravis Drugs Breakdown Data by Type
  • 8.3. Asia Pacific Myasthenia Gravis Drugs Breakdown Data by Application
  • 8.4. Asia Pacific Myasthenia Gravis Drugs Breakdown Data by Countries
    • 8.4.1. Asia Pacific Myasthenia Gravis Drugs Sales by Countries
    • 8.4.2. Asia Pacific Myasthenia Gravis Drugs Revenue by Countries
    • 8.4.3. China
    • 8.4.4. Japan
    • 8.4.5. Korea
    • 8.4.6. India
    • 8.4.7. Australia
    • 8.4.8. Indonesia
    • 8.4.9. Malaysia
    • 8.4.10. Philippines
    • 8.4.11. Thailand
    • 8.4.12. Vietnam

9. Central & South America

  • 9.1. Central & South America Myasthenia Gravis Drugs Breakdown Data by Company
  • 9.2. Central & South America Myasthenia Gravis Drugs Breakdown Data by Type
  • 9.3. Central & South America Myasthenia Gravis Drugs Breakdown Data by Application
  • 9.4. Central & South America Myasthenia Gravis Drugs Breakdown Data by Countries
    • 9.4.1. Central & South America Myasthenia Gravis Drugs Sales by Countries
    • 9.4.2. Central & South America Myasthenia Gravis Drugs Revenue by Countries
    • 9.4.3. Brazil

10. Middle East and Africa

  • 10.1. Middle East and Africa Myasthenia Gravis Drugs Breakdown Data by Type
  • 10.2. Middle East and Africa Myasthenia Gravis Drugs Breakdown Data by Application
  • 10.3. Middle East and Africa Myasthenia Gravis Drugs Breakdown Data by Countries
    • 10.3.1. Middle East and Africa Myasthenia Gravis Drugs Sales by Countries
    • 10.3.2. Middle East and Africa Myasthenia Gravis Drugs Revenue by Countries
    • 10.3.3. GCC Countries
    • 10.3.4. Egypt
    • 10.3.5. South Africa

11. Company Profiles

  • 11.1. Flamel Technologies
    • 11.1.1. Flamel Technologies Company Details
    • 11.1.2. Company Description and Business Overview
    • 11.1.3. Sales, Revenue and Market Share of Myasthenia Gravis Drugs
    • 11.1.4. Myasthenia Gravis Drugs Product Introduction
    • 11.1.5. Flamel Technologies Recent Development
  • 11.2. Roche
    • 11.2.1. Roche Company Details
    • 11.2.2. Company Description and Business Overview
    • 11.2.3. Sales, Revenue and Market Share of Myasthenia Gravis Drugs
    • 11.2.4. Myasthenia Gravis Drugs Product Introduction
    • 11.2.5. Roche Recent Development
  • 11.3. Grifols
    • 11.3.1. Grifols Company Details
    • 11.3.2. Company Description and Business Overview
    • 11.3.3. Sales, Revenue and Market Share of Myasthenia Gravis Drugs
    • 11.3.4. Myasthenia Gravis Drugs Product Introduction
    • 11.3.5. Grifols Recent Development
  • 11.4. Pfizer
    • 11.4.1. Pfizer Company Details
    • 11.4.2. Company Description and Business Overview
    • 11.4.3. Sales, Revenue and Market Share of Myasthenia Gravis Drugs
    • 11.4.4. Myasthenia Gravis Drugs Product Introduction
    • 11.4.5. Pfizer Recent Development
  • 11.5. Shire
    • 11.5.1. Shire Company Details
    • 11.5.2. Company Description and Business Overview
    • 11.5.3. Sales, Revenue and Market Share of Myasthenia Gravis Drugs
    • 11.5.4. Myasthenia Gravis Drugs Product Introduction
    • 11.5.5. Shire Recent Development
  • 11.6. Novartis
    • 11.6.1. Novartis Company Details
    • 11.6.2. Company Description and Business Overview
    • 11.6.3. Sales, Revenue and Market Share of Myasthenia Gravis Drugs
    • 11.6.4. Myasthenia Gravis Drugs Product Introduction
    • 11.6.5. Novartis Recent Development
  • 11.7. Valeant
    • 11.7.1. Valeant Company Details
    • 11.7.2. Company Description and Business Overview
    • 11.7.3. Sales, Revenue and Market Share of Myasthenia Gravis Drugs
    • 11.7.4. Myasthenia Gravis Drugs Product Introduction
    • 11.7.5. Valeant Recent Development
  • 11.8. Alexion
    • 11.8.1. Alexion Company Details
    • 11.8.2. Company Description and Business Overview
    • 11.8.3. Sales, Revenue and Market Share of Myasthenia Gravis Drugs
    • 11.8.4. Myasthenia Gravis Drugs Product Introduction
    • 11.8.5. Alexion Recent Development
  • 11.9. Catalyst
    • 11.9.1. Catalyst Company Details
    • 11.9.2. Company Description and Business Overview
    • 11.9.3. Sales, Revenue and Market Share of Myasthenia Gravis Drugs
    • 11.9.4. Myasthenia Gravis Drugs Product Introduction
    • 11.9.5. Catalyst Recent Development
  • 11.10. CSL
    • 11.10.1. CSL Company Details
    • 11.10.2. Company Description and Business Overview
    • 11.10.3. Sales, Revenue and Market Share of Myasthenia Gravis Drugs
    • 11.10.4. Myasthenia Gravis Drugs Product Introduction
    • 11.10.5. CSL Recent Development
  • 11.11. Curavac
  • 11.12. Cytokinetics
  • 11.13. Galencia
  • 11.14. GlaxoSmithKline
  • 11.15. Lupin Pharmaceuticals
  • 11.16. Mitsubishi Tanabe Pharma

12. Value Chain and Sales Channels Analysis

  • 12.1. Value Chain Analysis
  • 12.2. Sales Channels Analysis
    • 12.2.1. Myasthenia Gravis Drugs Sales Channels
    • 12.2.2. Myasthenia Gravis Drugs Distributors
  • 12.3. Myasthenia Gravis Drugs Customers

13. Market Forecast

  • 13.1. Global Myasthenia Gravis Drugs Sales and Revenue Forecast 2018-2025
  • 13.2. Global Myasthenia Gravis Drugs Sales Forecast by Type
  • 13.3. Global Myasthenia Gravis Drugs Sales Forecast by Application
  • 13.4. Myasthenia Gravis Drugs Forecast by Regions
    • 13.4.1. Global Myasthenia Gravis Drugs Sales Forecast by Regions 2018-2025
    • 13.4.2. Global Myasthenia Gravis Drugs Revenue Forecast by Regions 2018-2025
  • 13.5. North America Market Forecast
    • 13.5.1. North America Myasthenia Gravis Drugs Forecast by Countries 2018-2025
    • 13.5.2. United States
    • 13.5.3. Canada
    • 13.5.4. Mexico
  • 13.6. Europe Market Forecast
    • 13.6.1. Europe Myasthenia Gravis Drugs Forecast by Countries 2018-2025
    • 13.6.2. Germany
    • 13.6.3. France
    • 13.6.4. UK
    • 13.6.5. Italy
    • 13.6.6. Russia
  • 13.7. Asia Pacific Market Forecast
    • 13.7.1. Asia Pacific Myasthenia Gravis Drugs Sales Forecast by Countries 2018-2025
    • 13.7.2. China
    • 13.7.3. Japan
    • 13.7.4. Korea
    • 13.7.5. India
    • 13.7.6. Australia
    • 13.7.7. Indonesia
    • 13.7.8. Thailand
    • 13.7.9. Malaysia
    • 13.7.10. Philippines
    • 13.7.11. Vietnam
  • 13.8. Central & South America Market Forecast
    • 13.8.1. Central & South America Myasthenia Gravis Drugs Sales Forecast by Countries 2018-2025
    • 13.8.2. Brazil
  • 13.9. Middle East and Africa Market Forecast
    • 13.9.1. Middle East and Africa Myasthenia Gravis Drugs Sales Forecast by Countries 2018-2025
    • 13.9.2. GCC Countries
    • 13.9.3. Egypt
    • 13.9.4. South Africa

14. Research Findings and Conclusion

15. Appendix

  • 15.1. Research Methodology
    • 15.1.1. Methodology/Research Approach
      • 15.1.1.1. Research Programs/Design
      • 15.1.1.2. Market Size Estimation
      • 15.1.1.3. Market Breakdown and Data Triangulation
    • 15.1.2. Data Source
      • 15.1.2.1. Secondary Sources
      • 13.1.2.2. Primary Sources
  • 15.2. Author Details
  • 15.3. Disclaimer

List of Tables and Figures

  • Figure Myasthenia Gravis Drugs Product Picture
  • Table Myasthenia Gravis Drugs Key Market Segments
  • Table Major Manufacturers Myasthenia Gravis Drugs Covered in This Report
  • Table Global Myasthenia Gravis Drugs Market Size Growth Rate by Type 2018-2025 (MT) & (Million US$)
  • Figure Global Myasthenia Gravis Drugs Sales Market Shar by Type 2013-2025
  • Figure Anticholinesterases Figures
  • Table Major Manufacturers of Anticholinesterases
  • Figure Immunosuppressants Figures
  • Table Major Manufacturers of Immunosuppressants
  • Figure Intravenous Immune Globulins Figures
  • Table Major Manufacturers of Intravenous Immune Globulins
  • Table Global Myasthenia Gravis Drugs Market Share by Application 2018-2025 (MT)
  • Figure Hospitals Use Case
  • Figure Clinics Use Case
  • Figure Myasthenia Gravis Drugs Report Years Considered
  • Figure Global Myasthenia Gravis Drugs Market Size 2013-2025 (Million US$)
  • Figure Global Myasthenia Gravis Drugs Sales 2013-2018 (MT)
  • Table Global Myasthenia Gravis Drugs Market Size by Regions 2013-2018 (MT) & (Million US$)
  • Table Global Myasthenia Gravis Drugs Sales by Regions 2013-2018 (MT)
  • Table Global Myasthenia Gravis Drugs Sales Market Share by Regions 2013-2018
  • Figure Global Myasthenia Gravis Drugs Sales Market Share by Regions 2013-2018
  • Figure Global Myasthenia Gravis Drugs Sales Market Share by Regions in 2018
  • Table Global Myasthenia Gravis Drugs Revenue by Regions 2013-2018 (Million US$)
  • Table Global Myasthenia Gravis Drugs Revenue Market Share by Regions 2013-2018
  • Figure Global Myasthenia Gravis Drugs Revenue Market Share by Regions 2013-2018
  • Figure Global Myasthenia Gravis Drugs Revenue Market Share by Regions in 2018
  • Table Market Top Trends
  • Table Global Myasthenia Gravis Drugs Sales by Manufacturers (2013-2018) (MT)
  • Table Global Myasthenia Gravis Drugs Sales Share by Manufacturers (2013-2018)
  • Figure Global Myasthenia Gravis Drugs Sales Share by Manufacturers in 2018
  • Table Myasthenia Gravis Drugs Revenue by Manufacturers (2013-2018) (Million USD)
  • Table Myasthenia Gravis Drugs Revenue Share by Manufacturers (2013-2018)
  • Figure Myasthenia Gravis Drugs Value Share by Manufacturers in 2018
  • Table Global Myasthenia Gravis Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
  • Table Key Manufacturers Myasthenia Gravis Drugs Price (2013-2018) (USD/Kg)
  • Table Key Manufacturers Myasthenia Gravis Drugs Plants/Factories Distribution
  • Table Key Manufacturers Myasthenia Gravis Drugs Area Served
  • Table Date of Key Manufacturers Enter into Myasthenia Gravis Drugs Market
  • Table Key Manufacturers Myasthenia Gravis Drugs Product Type
  • Table Mergers & Acquisitions, Expansion Plans
  • Table Global Anticholinesterases Sales and Revenue (2013-2018) (MT) & (Million US$)
  • Table Global Immunosuppressants Sales and Revenue (2013-2018) (MT) & (Million US$)
  • Table Global Intravenous Immune Globulins Sales and Revenue (2013-2018) (MT) & (Million US$)
  • Table Global Myasthenia Gravis Drugs Sales by Type (2013-2018) (MT)
  • Table Global Myasthenia Gravis Drugs Sales Share by Type (2013-2018)
  • Figure Global Myasthenia Gravis Drugs Sales Market Share by Type (2013-2018)
  • Figure Global Myasthenia Gravis Drugs Sales Market Share by Type in 2017
  • Table Global Myasthenia Gravis Drugs Revenue by Type (2013-2018) (Million US$)
  • Table Global Myasthenia Gravis Drugs Revenue Share by Type (2013-2018)
  • Figure Global Myasthenia Gravis Drugs Revenue Market Share by Type (2013-2018)
  • Figure Global Myasthenia Gravis Drugs Revenue Market Share by Type in 2017
  • Table Myasthenia Gravis Drugs Price by Type 2013-2018 (USD/Kg)
  • Table Global Myasthenia Gravis Drugs Sales by Application (2013-2018) (MT)
  • Table Global Myasthenia Gravis Drugs Sales Share by Application (2013-2018)
  • Figure Global Sales Myasthenia Gravis Drugs Market Share by Application (2013-2018)
  • Figure Global Sales Myasthenia Gravis Drugs Market Share by Application in 2017
  • Figure North America Myasthenia Gravis Drugs Sales Growth Rate 2013-2018 (MT)
  • Figure North America Myasthenia Gravis Drugs Revenue Growth Rate 2013-2018 (Million US$)
  • Table North America Myasthenia Gravis Drugs Sales by Company (2013-2018) (MT)
  • Table North America Myasthenia Gravis Drugs Sales Market Share by Company (2013-2018)
  • Figure North America Myasthenia Gravis Drugs Sales Market Share by Company in 2018
  • Table North America Myasthenia Gravis Drugs Sales by Type (2013-2018) (MT)
  • Table North America Myasthenia Gravis Drugs Sales Market Share by Type (2013-2018)
  • Figure North America Myasthenia Gravis Drugs Market Share by Type in 2018
  • Table North America Myasthenia Gravis Drugs Sales by Application (2013-2018) (MT)
  • Table North America Myasthenia Gravis Drugs Sales Market Share by Application (2013-2018)
  • Figure North America Myasthenia Gravis Drugs Market Share by Application in 2018
  • Table North America Myasthenia Gravis Drugs Sales by Countries (2013-2018) (MT)
  • Table North America Myasthenia Gravis Drugs Sales Market Share by Countries (2013-2018)
  • Figure 2017 North America Myasthenia Gravis Drugs Sales Market Share by Countries
  • Table North America Myasthenia Gravis Drugs Revenue by Countries (2013-2018) (Million US$)
  • Table North America Myasthenia Gravis Drugs Revenue Market Share by Countries (2013-2018)
  • Figure 2017 North America Myasthenia Gravis Drugs Revenue Market Share by Countries
  • Figure United States Myasthenia Gravis Drugs Sales Growth Rate (2013-2018) (MT)
  • Figure Canada Myasthenia Gravis Drugs Sales Growth Rate (2013-2018) (MT)
  • Figure Mexico Myasthenia Gravis Drugs Sales Growth Rate (2013-2018) (MT)
  • Figure Europe Myasthenia Gravis Drugs Sales Growth Rate 2013-2018 (MT)
  • Figure Europe Myasthenia Gravis Drugs Revenue Growth Rate 2013-2018 (Million US$)
  • Table Europe Myasthenia Gravis Drugs Sales by Company (2013-2018) (MT)
  • Table Europe Myasthenia Gravis Drugs Sales Market Share by Company (2013-2018)
  • Figure Europe Myasthenia Gravis Drugs Sales Market Share by Company in 2018
  • Table Europe Myasthenia Gravis Drugs Sales by Type (2013-2018) (MT)
  • Table Europe Myasthenia Gravis Drugs Sales Market Share by Type (2013-2018)
  • Figure 2017 Europe Myasthenia Gravis Drugs Market Share by Type
  • Table Europe Myasthenia Gravis Drugs Sales by Application (2013-2018) (MT)
  • Table Europe Myasthenia Gravis Drugs Sales Market Share by Application (2013-2018)
  • Figure 2017 Europe Myasthenia Gravis Drugs Market Share by Application
  • Table Europe Myasthenia Gravis Drugs Sales by Countries (2013-2018) (MT)
  • Table Europe Myasthenia Gravis Drugs Sales Market Share by Countries (2013-2018)
  • Figure 2017 Europe Myasthenia Gravis Drugs Sales Market Share by Countries
  • Table Europe Myasthenia Gravis Drugs Revenue by Countries (2013-2018) (Million US$)
  • Table Europe Myasthenia Gravis Drugs Revenue Market Share by Countries (2013-2018)
  • Figure Europe Myasthenia Gravis Drugs Revenue Market Share by Countries in 2018
  • Figure Germany Myasthenia Gravis Drugs Sales Growth Rate (2013-2018) (MT)
  • Figure France Myasthenia Gravis Drugs Sales Growth Rate (2013-2018) (MT)
  • Figure UK Myasthenia Gravis Drugs Sales Growth Rate (2013-2018) (MT)
  • Figure Italy Myasthenia Gravis Drugs Sales Growth Rate (2013-2018) (MT)
  • Figure Russia Myasthenia Gravis Drugs Sales Growth Rate (2013-2018) (MT)
  • Figure Asia Pacific Myasthenia Gravis Drugs Sales Growth Rate 2013-2018 (MT)
  • Figure Asia Pacific Myasthenia Gravis Drugs Revenue Growth Rate 2013-2018 (Million US$)
  • Table Asia Pacific Myasthenia Gravis Drugs Sales by Company (2013-2018) (MT)
  • Table Asia Pacific Myasthenia Gravis Drugs Sales Market Share by Company (2013-2018)
  • Figure Asia Pacific Myasthenia Gravis Drugs Sales Market Share by Company in 2018
  • Table Asia Pacific Myasthenia Gravis Drugs Sales by Type (2013-2018) (MT)
  • Table Asia Pacific Myasthenia Gravis Drugs Sales Market Share by Type (2013-2018)
  • Figure Asia Pacific Myasthenia Gravis Drugs Market Share by Type in 2018
  • Table Asia Pacific Myasthenia Gravis Drugs Sales by Application (2013-2018) (MT)
  • Table Asia Pacific Myasthenia Gravis Drugs Sales Market Share by Application (2013-2018)
  • Figure Asia Pacific Myasthenia Gravis Drugs Market Share by Application in 2018
  • Table Asia Pacific Myasthenia Gravis Drugs Sales by Countries (2013-2018) (MT)
  • Table Asia Pacific Myasthenia Gravis Drugs Sales Market Share by Countries (2013-2018)
  • Figure 2017 Asia Pacific Myasthenia Gravis Drugs Sales Market Share by Countries
  • Table Asia Pacific Myasthenia Gravis Drugs Revenue by Countries (2013-2018) (Million US$)
  • Table Asia Pacific Myasthenia Gravis Drugs Revenue Market Share by Countries (2013-2018)
  • Figure 2017 Asia Pacific Myasthenia Gravis Drugs Revenue Market Share by Countries
  • Figure China Myasthenia Gravis Drugs Sales Growth Rate (2013-2018) (MT)
  • Figure China Myasthenia Gravis Drugs Revenue Growth Rate (2013-2018) (Million US$)
  • Figure Japan Myasthenia Gravis Drugs Sales Growth Rate (2013-2018) (MT)
  • Figure Japan Myasthenia Gravis Drugs Revenue Growth Rate (2013-2018) (Million US$)
  • Figure Korea Myasthenia Gravis Drugs Sales Growth Rate (2013-2018) (MT)
  • Figure Korea Myasthenia Gravis Drugs Revenue Growth Rate (2013-2018) (Million US$)
  • Figure India Myasthenia Gravis Drugs Sales Growth Rate (2013-2018) (MT)
  • Figure India Myasthenia Gravis Drugs Revenue Growth Rate (2013-2018) (Million US$)
  • Figure Australia Myasthenia Gravis Drugs Sales Growth Rate (2013-2018) (MT)
  • Figure Australia Myasthenia Gravis Drugs Revenue Growth Rate (2013-2018) (Million US$)
  • Figure Indonesia Myasthenia Gravis Drugs Sales Growth Rate (2013-2018) (MT)
  • Figure Indonesia Myasthenia Gravis Drugs Revenue Growth Rate (2013-2018) (Million US$)
  • Figure Malaysia Myasthenia Gravis Drugs Sales Growth Rate (2013-2018) (MT)
  • Figure Malaysia Myasthenia Gravis Drugs Revenue Growth Rate (2013-2018) (Million US$)
  • Figure Philippines Myasthenia Gravis Drugs Sales Growth Rate (2013-2018) (MT)
  • Figure Philippines Myasthenia Gravis Drugs Revenue Growth Rate (2013-2018) (Million US$)
  • Figure Thailand Myasthenia Gravis Drugs Sales Growth Rate (2013-2018) (MT)
  • Figure Thailand Myasthenia Gravis Drugs Revenue Growth Rate (2013-2018) (Million US$)
  • Figure Vietnam Myasthenia Gravis Drugs Sales Growth Rate (2013-2018) (MT)
  • Figure Vietnam Myasthenia Gravis Drugs Revenue Growth Rate (2013-2018) (Million US$)
  • Figure Central & South America Myasthenia Gravis Drugs Sales Growth Rate 2013-2018 (MT)
  • Figure Central & South America Myasthenia Gravis Drugs Revenue Growth Rate 2013-2018 (Million US$)
  • Table Central & South America Myasthenia Gravis Drugs Sales by Company (2013-2018) (MT)
  • Table Central & South America Myasthenia Gravis Drugs Sales Market Share by Company (2013-2018)
  • Figure Central & South America Myasthenia Gravis Drugs Sales Market Share by Company in 2018
  • Table Central & South America Myasthenia Gravis Drugs Sales by Type (2013-2018) (MT)
  • Table Central & South America Myasthenia Gravis Drugs Sales Market Share by Type (2013-2018)
  • Figure Central & South America Myasthenia Gravis Drugs Market Share by Type in 2018
  • Table Central & South America Myasthenia Gravis Drugs Sales by Application (2013-2018) (MT)
  • Table Central & South America Myasthenia Gravis Drugs Sales Market Share by Application (2013-2018)
  • Figure Central & South America Myasthenia Gravis Drugs Market Share by Application in 2018
  • Table Central & South America Myasthenia Gravis Drugs Sales by Countries (2013-2018) (MT)
  • Table Central & South America Myasthenia Gravis Drugs Sales Market Share by Countries (2013-2018)
  • Figure Central & South America Myasthenia Gravis Drugs Sales Market Share by Countries in 2018
  • Table Central & South America Myasthenia Gravis Drugs Revenue by Countries (2013-2018) (Million US$)
  • Table Central & South America Myasthenia Gravis Drugs Revenue Market Share by Countries (2013-2018)
  • Figure Central & South America Myasthenia Gravis Drugs Revenue Market Share by Countries in 2018
  • Figure Brazil Myasthenia Gravis Drugs Sales Growth Rate (2013-2018) (MT)
  • Figure Brazil Myasthenia Gravis Drugs Revenue Growth Rate (2013-2018) (MT)
  • Figure Middle East and Africa Myasthenia Gravis Drugs Sales Growth Rate 2013-2018 (MT)
  • Figure Middle East and Africa Myasthenia Gravis Drugs Revenue Growth Rate 2013-2018 (Million US$)
  • Table Middle East and Africa Myasthenia Gravis Drugs Sales by Type (2013-2018) (MT)
  • Table Middle East and Africa Myasthenia Gravis Drugs Sales Market Share by Type (2013-2018)
  • Figure 2017 Middle East and Africa Myasthenia Gravis Drugs Market Share by Type
  • Table Middle East and Africa Myasthenia Gravis Drugs Sales by Application (2013-2018) (MT)
  • Table Middle East and Africa Myasthenia Gravis Drugs Sales Market Share by Application (2013-2018)
  • Figure 2017 Middle East and Africa Myasthenia Gravis Drugs Market Share by Application
  • Table Middle East and Africa Myasthenia Gravis Drugs Sales by Countries (2013-2018) (MT)
  • Table Middle East and Africa Myasthenia Gravis Drugs Sales Market Share by Countries (2013-2018)
  • Figure 2017 Middle East and Africa Myasthenia Gravis Drugs Sales Market Share by Countries
  • Table Middle East and Africa Myasthenia Gravis Drugs Revenue by Countries (2013-2018) (Million US$)
  • Table Middle East and Africa Myasthenia Gravis Drugs Revenue Market Share by Countries (2013-2018)
  • Figure 2017 Middle East and Africa Myasthenia Gravis Drugs Revenue Market Share by Countries
  • Figure GCC Countries Myasthenia Gravis Drugs Sales Growth Rate (2013-2018) (MT)
  • Figure GCC Countries Myasthenia Gravis Drugs Revenue Growth Rate (2013-2018) (MT)
  • Figure Egypt Myasthenia Gravis Drugs Sales Growth Rate (2013-2018) (MT)
  • Figure Egypt Myasthenia Gravis Drugs Revenue Growth Rate (2013-2018) (MT)
  • Figure South Africa Myasthenia Gravis Drugs Sales Growth Rate (2013-2018) (MT)
  • Figure South Africa Myasthenia Gravis Drugs Revenue Growth Rate (2013-2018) (MT)
  • Table Flamel Technologies Company Details
  • Table Flamel Technologies Description and Business Overview
  • Table Flamel Technologies Myasthenia Gravis Drugs Sales (MT), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2013-2018)
  • Table Flamel Technologies Myasthenia Gravis Drugs Sales Growth Rate (2013-2018)
  • Table Flamel Technologies Myasthenia Gravis Drugs Sales Market Share in Global Market
  • Table Flamel Technologies Recent Development
  • Table Roche Company Details
  • Table Roche Description and Business Overview
  • Table Roche Myasthenia Gravis Drugs Sales (MT), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2013-2018)
  • Table Roche Myasthenia Gravis Drugs Sales Growth Rate (2013-2018)
  • Table Roche Myasthenia Gravis Drugs Sales Market Share in Global Market
  • Table Roche Recent Development
  • Table Grifols Company Details
  • Table Grifols Description and Business Overview
  • Table Grifols Myasthenia Gravis Drugs Sales (MT), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2013-2018)
  • Table Grifols Myasthenia Gravis Drugs Sales Growth Rate (2013-2018)
  • Table Grifols Myasthenia Gravis Drugs Sales Market Share in Global Market
  • Table Grifols Recent Development
  • Table Pfizer Company Details
  • Table Pfizer Description and Business Overview
  • Table Pfizer Myasthenia Gravis Drugs Sales (MT), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2013-2018)
  • Table Pfizer Myasthenia Gravis Drugs Sales Growth Rate (2013-2018)
  • Table Pfizer Myasthenia Gravis Drugs Sales Market Share in Global Market
  • Table Pfizer Recent Development
  • Table Shire Company Details
  • Table Shire Description and Business Overview
  • Table Shire Myasthenia Gravis Drugs Sales (MT), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2013-2018)
  • Table Shire Myasthenia Gravis Drugs Sales Growth Rate (2013-2018)
  • Table Shire Myasthenia Gravis Drugs Sales Market Share in Global Market
  • Table Shire Recent Development
  • Table Novartis Company Details
  • Table Novartis Description and Business Overview
  • Table Novartis Myasthenia Gravis Drugs Sales (MT), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2013-2018)
  • Table Novartis Myasthenia Gravis Drugs Sales Growth Rate (2013-2018)
  • Table Novartis Myasthenia Gravis Drugs Sales Market Share in Global Market
  • Table Novartis Recent Development
  • Table Valeant Company Details
  • Table Valeant Description and Business Overview
  • Table Valeant Myasthenia Gravis Drugs Sales (MT), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2013-2018)
  • Table Valeant Myasthenia Gravis Drugs Sales Growth Rate (2013-2018)
  • Table Valeant Myasthenia Gravis Drugs Sales Market Share in Global Market
  • Table Valeant Recent Development
  • Table Alexion Company Details
  • Table Alexion Description and Business Overview
  • Table Alexion Myasthenia Gravis Drugs Sales (MT), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2013-2018)
  • Table Alexion Myasthenia Gravis Drugs Sales Growth Rate (2013-2018)
  • Table Alexion Myasthenia Gravis Drugs Sales Market Share in Global Market
  • Table Alexion Recent Development
  • Table Catalyst Company Details
  • Table Catalyst Description and Business Overview
  • Table Catalyst Myasthenia Gravis Drugs Sales (MT), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2013-2018)
  • Table Catalyst Myasthenia Gravis Drugs Sales Growth Rate (2013-2018)
  • Table Catalyst Myasthenia Gravis Drugs Sales Market Share in Global Market
  • Table Catalyst Recent Development
  • Table CSL Company Details
  • Table CSL Description and Business Overview
  • Table CSL Myasthenia Gravis Drugs Sales (MT), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2013-2018)
  • Table CSL Myasthenia Gravis Drugs Sales Growth Rate (2013-2018)
  • Table CSL Myasthenia Gravis Drugs Sales Market Share in Global Market
  • Table CSL Recent Development
  • Table Curavac Company Details
  • Table Cytokinetics Company Details
  • Table Galencia Company Details
  • Table GlaxoSmithKline Company Details
  • Table Lupin Pharmaceuticals Company Details
  • Table Mitsubishi Tanabe Pharma Company Details
  • Figure Myasthenia Gravis Drugs Value Chain
  • Table Myasthenia Gravis Drugs Distributors List
  • Table Myasthenia Gravis Drugs Customers List
  • Table Global Myasthenia Gravis Drugs Sales Forecast 2018-2025 (MT) & (Million US$)
  • Figure Global Myasthenia Gravis Drugs Sales Forecast 2018-2025 (MT)
  • Figure Global Myasthenia Gravis Drugs Revenue Forecast 2018-2025 (Million US$)
  • Table Global Myasthenia Gravis Drugs Sales Forecast by Type 2018-2025 (MT)
  • Figure Global Myasthenia Gravis Drugs Sales Forecast by Type 2018-2025 (MT)
  • Figure Global Myasthenia Gravis Drugs Sales Market Share Forecast by Type 2018-2025
  • Table Global Myasthenia Gravis Drugs Sales Forecast by Application 2018-2025 (MT)
  • Figure Global Myasthenia Gravis Drugs Sales Forecast by Application 2018-2025 (MT)
  • Figure Global Myasthenia Gravis Drugs Sales Market Share Forecast by Application 2018-2025
  • Table Global Myasthenia Gravis Drugs Sales Forecast by Regions 2018-2025 (MT)
  • Figure Global Myasthenia Gravis Drugs Sales Forecast by Regions 2018-2025 (MT)
  • Figure Global Myasthenia Gravis Drugs Sales Market Share Forecast by Regions 2018-2025
  • Table Global Myasthenia Gravis Drugs Revenue Forecast by Regions 2018-2025 (Million US$)
  • Figure Global Myasthenia Gravis Drugs Revenue Forecast by Regions 2018-2025 (Million US$)
  • Figure Global Myasthenia Gravis Drugs Revenue Market Share Forecast by Regions 2018-2025
  • Table North America Myasthenia Gravis Drugs Sales Forecast by Countries 2018-2025 (MT)
  • Table North America Myasthenia Gravis Drugs Sales Market Share Forecast by Countries 2018-2025
  • Table North America Myasthenia Gravis Drugs Revenue Forecast by Countries 2018-2025 (Million US$)
  • Table North America Myasthenia Gravis Drugs Revenue Market Share Forecast by Countries 2018-2025
  • Figure United States Myasthenia Gravis Drugs Sales Forecast 2018-2025 (MT)
  • Figure Canada Myasthenia Gravis Drugs Sales Forecast 2018-2025 (MT)
  • Figure MexicoMyasthenia Gravis Drugs Sales Forecast 2018-2025 (MT)
  • Table Europe Myasthenia Gravis Drugs Sales Forecast by Countries 2018-2025 (MT)
  • Table Europe Myasthenia Gravis Drugs Sales Market Share Forecast by Countries 2018-2025
  • Table Europe Myasthenia Gravis Drugs Revenue Forecast by Countries 2018-2025 (Million US$)
  • Table Europe Myasthenia Gravis Drugs Revenue Market Share Forecast by Countries 2018-2025
  • Figure Germany Myasthenia Gravis Drugs Sales Forecast 2018-2025 (MT)
  • Figure France Myasthenia Gravis Drugs Sales Forecast 2018-2025 (MT)
  • Figure UK Myasthenia Gravis Drugs Sales Forecast 2018-2025 (MT)
  • Figure Italy Myasthenia Gravis Drugs Sales Forecast 2018-2025 (MT)
  • Figure Russia Myasthenia Gravis Drugs Sales Forecast 2018-2025 (MT)
  • Table Asia Pacific Myasthenia Gravis Drugs Sales Forecast by Countries 2018-2025 (MT)
  • Table Asia Pacific Myasthenia Gravis Drugs Sales Market Share Forecast by Countries 2018-2025
  • Table Asia Pacific Myasthenia Gravis Drugs Revenue Forecast by Countries 2018-2025 (Million US$)
  • Table Asia Pacific Myasthenia Gravis Drugs Revenue Market Share Forecast by Countries 2018-2025
  • Figure China Myasthenia Gravis Drugs Sales Forecast 2018-2025 (MT)
  • Figure Japan Myasthenia Gravis Drugs Sales Forecast 2018-2025 (MT)
  • Figure Korea Myasthenia Gravis Drugs Sales Forecast 2018-2025 (MT)
  • Figure India Myasthenia Gravis Drugs Sales Forecast 2018-2025 (MT)
  • Figure Australia Myasthenia Gravis Drugs Sales Forecast 2018-2025 (MT)
  • Figure Indonesia Myasthenia Gravis Drugs Sales Forecast 2018-2025 (MT)
  • Figure Thailand Myasthenia Gravis Drugs Sales Forecast 2018-2025 (MT)
  • Figure Malaysia Myasthenia Gravis Drugs Sales Forecast 2018-2025 (MT)
  • Figure Philippines Myasthenia Gravis Drugs Sales Forecast 2018-2025 (MT)
  • Figure Vietnam Myasthenia Gravis Drugs Sales Forecast 2018-2025 (MT)
  • Table Central & South America Myasthenia Gravis Drugs Sales Forecast by Countries 2018-2025 (MT)
  • Table Central & South America Myasthenia Gravis Drugs Sales Market Share Forecast by Countries 2018-2025
  • Table Central & South America Myasthenia Gravis Drugs Revenue Forecast by Countries 2018-2025 (Million US$)
  • Table Central & South America Myasthenia Gravis Drugs Revenue Market Share Forecast by Countries 2018-2025
  • Figure Brazil Myasthenia Gravis Drugs Sales Forecast 2018-2025 (MT)
  • Table Middle East and Africa Myasthenia Gravis Drugs Sales Forecast by Regions 2018-2025 (MT)
  • Table Middle East and Africa Myasthenia Gravis Drugs Sales Market Share Forecast by Regions 2018-2025
  • Table Middle East and Africa Myasthenia Gravis Drugs Revenue Forecast by Regions 2018-2025 (Million US$)
  • Table Middle East and Africa Myasthenia Gravis Drugs Revenue Market Share Forecast by Regions 2018-2025
  • Figure GCC Countries Myasthenia Gravis Drugs Sales Growth Rate (2016-2025) (MT)
  • Figure Egypt Myasthenia Gravis Drugs Sales Growth Rate (2016-2025) (MT)
  • Figure South Africa Myasthenia Gravis Drugs Sales Growth Rate (2016-2025) (MT)
  • Table Research Programs/Design for This Report
  • Figure Bottom-up and Top-down Approaches for This Report
  • Figure Data Triangulation
  • Table Key Data Information from Secondary Sources
  • Table Key Data Information from Primary Sources
Back to Top